Kodiak Sciences Inc. (KOD), headquartered in Palo Alto, California, is a leading biopharmaceutical company focused on creating valuable pharmaceuticals to treat chronic, high-prevalence retinal diseases. Kodiak, which was founded in 2009, is ambitious and determined to revolutionize the retinal medicine field, driven by its profound commitment to patients.
Under the leadership of CEO Victor Perlroth, MD, Kodiak aims to capture the benefits of continuous innovation in the fields of therapeutic discovery, development, and manufacturing. The company’s philosophy is rooted in scientific excellence and rigorous data-driven decision making.
Kodiak's flagship innovation is KSI-301, a novel anti-VEGF (Vascular Endothelial Growth Factor) compound developed using the company’s proprietary ABC Platform. This product highlights Kodiak's dedication to scientific novelty, as it is designed to maintain potent and effective drug levels in eye tissues for longer than existing treatment options. Trials of KSI-301 have shown significant potential in treating various retinal diseases, such as wet age-related macular degeneration (AMD), retinal vein occlusion (RVO), and diabetic macular edema (DME), without the need for as frequent injections, thereby reducing the treatment burden for patients.
With its continuous efforts to establish clinical-stage proof of concept, Kodiak remains poised to further evaluate and progress its pipeline of retina disease therapies. This long-term vision and commitment to innovation set the company apart, placing it in a strong position to shape the future of retinal disease therapy.
The stock market debut of Kodiak Sciences Inc (KOD) took place in October 2018. Since then, the company has continued to grow steadily in the competitive biotechnology industry, supported by its robust drug development pipeline and dedication to patients. Kodiak's shares are traded on the Nasdaq Global Select Market under the ticker symbol "KOD.”
In short, Kodiak Sciences Inc. (KOD) is taking strides toward transforming retinal medical treatment. Its development of revolutionary therapeutics, paired with its passion for helping patients grappling with retinal diseases, positions the company as a game-changer within the biotechnology realm.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Kodiak Sciences is nearing the release of top-line results from its phase III DAYBREAK trial for Zenkuda and KSI-501, targeting wet age-related macular degeneration. The outcome of this trial is critical for the company, given its focus on a single retinal platform, current lack of significant revenue, and limited cash runway. The results will heavily influence investor perception of its potential in the multi-billion dollar anti-VEGF market and the credibility of its entire retinal vascular pipeline.
This Zacks Analyst Blog highlights four biotech stocks—Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX)—that are poised for significant clinical readouts this fall. These readouts, spanning various therapeutic areas, are crucial catalysts for these companies, with potential to materially shift investor expectations and stock prices based on study results. The article details the specific late-stage studies and anticipated data releases for each company, emphasizing their potential impact on future regulatory and commercial prospects.
This article highlights four biotech stocks – Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX) – that have significant clinical readouts anticipated in the fall, which could dramatically impact their valuations. These readouts cover various therapeutic areas including ophthalmology, immunology, neuroscience, and vaccines. The companies' future prospects hinge on these study results, making them key watch targets for investors.
Kodiak Sciences is awaiting Phase 3 DAYBREAK results for its treatments Zenkuda and KSI-501 for wet AMD this month. While the company has a chance to introduce a longer-lasting treatment, the key challenge is whether the clinical results will provide enough compelling reasons for physicians to adopt them, especially considering the current $2.1 billion valuation which already anticipates positive outcomes. The author rates KOD as a Hold, noting that a routine positive headline may not justify the current valuation given the need for significant advancements in patient vision and dosing intervals to truly succeed.
Kodiak Sciences Inc. reported a widening net loss in Q2 2026 and for the first half of 2026, though its basic loss per share for H1 improved. The company, a pre-revenue biopharmaceutical firm, continues to rely on the success of its eye disease pipeline, particularly KSI-101 and Zenkuda, to offset its significant cash burn. Investors are closely watching trial milestones and the company's limited cash runway, which suggests a potential need for fresh capital.
GSA Capital Partners LLP acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, purchasing 27,525 shares valued at approximately $1.07 million. Institutional investors and hedge funds now own 89.06% of Kodiak Sciences stock. Analyst sentiment for the company is a "Moderate Buy" with an average price target of $48.14, despite missing recent quarterly earnings estimates.
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating for Kodiak Sciences (KOD), maintaining a price target of $58.00 despite the company's current stock price of $41.37. The company, which operates in the biotechnology sector and focuses on retinal medicines, has a low GF Score™ of 27/100, indicating areas for improvement in profitability and growth. Insider activity shows $1.0 million in selling over the last three months with no buying, and guru ownership is mixed.